CLINICAL AND DIAGNOSTIC SIGNIFICANCE OF STIMULATING GROWTH FACTOR (ST2) FOR EVALUATION OF EARLY COMPLICATIONS IN MYOCARDIAL INFARCTION

Aim: The aim of the study was to determine the ST2 and NT­proBNP contents in blood serum of patients with myocardial infarction (MI) during in­hospital follow up depending on the presence of hospital complications and to elucidate their relationships with the types of myocardial remodeling. Materials and Methods: A total of 88 MI patients aged 59±8.36 years were studied. At days 1 and 12, the ST2 and NT­proBNP contents were assessed in blood serum by the immunoenzyme method. Control group comprised 30 patients. Statistical analysis of data was performed by non­parametric criteria. Results: ST2 level was by 2 times higher in patients with unfavorable outcome at day 1 of in­hospital period than in patients with favorable MI course and by 3.7 times higher than in control. A decrease in the level of the marker was observed at day 12 in both groups. At day 1 of MI, the level of NT­proBNP was by 6.8 times higher in patients with unfavorable prognosis than in control and by 1.8 times higher than in group of favorable course. At day 12, the levels of NT­proBNP remained increased in both groups. Determination of ST2 in a combination with NT­proBNP enhanced their diagnostic value (OR 1.92; 95%CI (1.7–3.2) AUG=0.89; р=0.004). High level of ST2 at day 1 of MI was associated with disadaptive variant of remodeling and exceeded by 1.5 times the corresponding value in group of adaptive remodeling (OR=4.5, 95%CI=2.0­10.1; р=0.011; AUG=0.81) unlike the NT­proBNP content that was similar in both groups during the entire in­hospital period. Conclusions: (1) The course of in­hospital MI period was characterized by the high contents of ST2 and NT­proBNP in blood serum. (2) Complications of in­hospital MI period were associated with higher levels of ST2 compared with NT­proBNP. However, the combined use of the ST2 and NT­proBNP values demonstrated higher diagnostic sensitivity and specificity. (3) Increased content of ST2 in blood serum was accompanied by the development of disadaptive variant of heart remodeling. 

1. Lupon J., de Antonio M., Galan A. et al. Combined use of the novel biomarkers highsensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment // Mayo Clin. Proc. – 2013. – Vol. 88(3). – Р. 234–243.

2. Braunwald E. Biomarkers in heart failure // New Engl. J. Med. – 2008. – Vol. 358. – P. 2148–2159.

3. Lindenfeld J., Albert N.M., Boehmer J.P. et al. Heart Failure Society of America. HFSA 2010 Comprehensive Heart Failure Practice Guideline // J. Card. Fail. –2010. – Vol. 16(6). – Р. e1–e194.

4. Schmitz J., Owyang A., Oldham E. et al. Il¬33, and interleukin-1-like cytokine that signals via the Il¬1 receptor¬related protein ST2 and induces T helper type 2-associated cytokines // Immunity. – 2005. – Vol. 23. – Р. 479–490.

5. Kakkar R., Lee R.T. The IL-33/ST2 pathway: therapeutic target and novel biomarker // Nat. Rev. Drug Discov. – 2008. – Vol. 7. – Р. 827–840.

6. Sabatine M.S., Morrow D.A., Higgins L.J. et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST¬ elevation myocardial infarction // Circulation. – 2008. – Vol. 117. – Р. 1936–1944.

7. Shimpo M., Morrow D.A., Weinberg E.O. et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction // Circulation. – 2004. – Vol. 109. – Р. 2186–2190.

8. Sutton J.M., Pfeffer M.A., Plappert T. et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril // Circulation. – 1994. – Vol. 89. – Р. 68–75.

9. Brzezinska B., Lobos-Grudzien K., Sokalski L. Patterns of post MI left ventricular volume changes – clinical implications // Kardiol. Pol. – 2007. – Vol. 65. – Р. 1190–1198.

10. Hlatky M.A., Greenland P., Arnett D.K. et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association // Circulation. – 2009. – Vol. 119. – Р. 2408–2416.

11. O’Connor C.M., Hasselblad V., Mehta R.H. et al. Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score // J. Am. Coll. Cardiol. – 2010. – Vol. 55. – Р. 872–878.

12. Ciccone M.M., Cortese F., Gesualdo M. et al. A novel cardiac biomarker: ST2: a review // Molecules. – 2013. – Vol. 18. – Р. 15314– 15328.

13. Maries L., Manitiu I. Diagnostic and prognostic values of B¬type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP) // Cardiovasc. J. Afr. – 2013. – Vol. 7. – Р. 286–289.

14. Bayes¬Genis A., de Antonio M., Galan A. et al. Combined use of high sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure // Eur. J. Heart Fail. – 2012. – Vol. 14(1). – Р. 32–38.

15. Бокерия Л.А., Бокерия О.Л., Ле Т.Г. Электрофизиологическое ремоделирование миокарда при сердечной недостаточности и различных заболеваниях сердца. // Анналы аритмологии. – 2010 – № 4 – C. 41–48.